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BACKGROUND. Increased expression of the hepatocyte growth factor (HGF) receptor (MET)
is associated with high-grade prostatic adenocarcinoma and metastasis. However, the
mechanism through which MET signaling contributes to prostate cancer (CaP) metastasis
remains unclear.
METHODS. Human PC-3 CaP cells and in vivo selected, isogeneic variant cells of increasing
metastatic potential (PC-3M, PC-3M-Pro4, and PC-3M-LN4) were used to investigate the effect
of HGF on CaP cell growth, protease production, and invasion. Cell-free urokinase-type
plasminogen activator (u-PA) expression and function following HGF treatment were analyzed
by Western blot, ELISA, and casein/plasminogen zymography. In vitro invasion stimulated by
HGF was measured using Matrigel-coated invasion chambers.
RESULTS. Both mRNA and functional protein for MET were detected in each of the CaP cell
lines. HGF treatment (0–40 ng/ml) weakly increase proliferation, however, HGF induced
soluble u-PA protein and activity 3-fold in the metastatic variant cells. HGF significantly
stimulated the invasion of highly metastatic PC-3M-LN4 cells through Matrigel and treatment
with specific urokinase receptor inhibitors diminished the HGF-stimulated invasion in a dose-
dependent manner.
CONCLUSIONS. These results demonstrate the biological significance of u-PA up-regulation
in response to HGF in highly metastatic hormone refractory CaP cells. Prostate 59: 167–176,
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INTRODUCTION
Osteoblastic lesions of the pelvis and vertebral
column are the most frequent distant metastases form-
ed in human prostate cancer (CaP). Recent autopsy
data suggest that more than 80% of all men who die of
CaP have metastatic disease in the bone [1,2]. Analysis
of factors present in the bone microenvironment may
yield important information regarding the high pre-
valence of bone metastases in human CaP.
Hepatocyte growth factor (HGF) or scatter factor, is
expressed in the bone microenvironment. HGF signals
through the receptor tyrosine kinase MET to mediate
(in a cell-type specific manner) invasion, survival,
proliferation, migration, morphogenesis, and angio-
genesis [3]. Human bone stromal cells have been shown
to express HGF [4,5] and human bone marrow stromal
fibroblasts specifically stimulate the growth of LNCaP
cells in vivo [6]. HGF has also been reported to promote
CaP colony formation on bone marrow stromal cells
in vitro [7]. Immunohistochemical analysis of CaP
surgical specimens has demonstrated a relationship
between MET expression and CaP progression [8,9].
These analyses have revealed that bone and lymph
node metastatic CaP cells have a higher frequency of
MET expression compared to CaP metastases at other
sites suggesting an increased significance of MET
expression in the context of the bone [8]. Taken
together, the data suggest that CaP cells are responsive
to HGF, which may promote CaP cell growth in the
bone environment.
HGF is secreted as an inactive, single chain protein
and is sequestered in the extracellular space by
heparin-sulfate proteoglycans [10,11]. To become
active, HGF must be cleaved into a two-chain hetero-
dimer by the action of serine proteases. Urokinase-type
plasminogen activator (u-PA) is a serine protease that
has been shown to activate HGF in vitro [12–15]. It is
unclear whether HGF is a physiological substrate for
u-PA in vivo. However, during liver regeneration,
hepatocyte-derived u-PA is believed to initiate ECM
degradation that results in the release and subsequent
activation of HGF [16,17]. In a similar fashion, meta-
static tumor cells may generate increased HGF levels in
the organ microenvironment through the production of
u-PA. Recent evidence has further demonstrated that
HGF can in turn effect u-PA expression. A number of
cell lines have been shown to up-regulate u-PA in
response to HGF in vitro [18–26] presumably through
increased transcription following Map kinase/AP-1
activation down stream of MET [27]. CaP cell lines have
been shown to express u-PA in vitro and u-PA over
expression in Mat Ly Lu CaP cells was shown to
enhance bone metastasis following intracardiac injec-
tion. The demonstration that u-PA can activate HGF
and that HGF can in turn increase u-PA expression
suggests that u-PA and HGF are part of a paracrine
loop which may promote tumor cell invasion in vivo.
However, the mechanism through which HGF/MET
signaling contribute to CaP metastasis remains unclear.
To address this question, we examined whether
HGF/MET signaling mediates the invasiveness of CaP
cells through HGFs ability to induce the expression of
proteases associated with metastasis. We report that
HGF can up-regulate u-PA protein production and
stimulate invasion through Matrigel of highly meta-
static human CaP cells. Moreover, we provide evidence
that the mechanism for this effect is u-PA dependent as
inhibitors that target the urokinase receptor diminish
HGF-stimulated invasion.
MATERIALSANDMETHODS
Cells andCultureConditions
The human PC-3 CaP cell line was obtained from the
American Type Culture Collection (Rockville, MD).
PC-3M was established from liver metastases pro-
duced in nude mice subsequent to intrasplenic injec-
tion of PC-3 cells [28]. Low-metastatic PC-3M-Pro4 cells
were generated following the initial intraprostatic
injection of PC-3M cells and subsequent orthotopic
cycling of resultant prostate tumor cells four rounds
into the prostate of nude mice [29]. Likewise, high-
metastatic PC-3M-LN4 cells were isolated from the
parental PC-3M cells subsequent to intraprostatic in-
jection and in vivo recycling of lymph node tumor cells
[29]. All cell lines were maintained on plastic in RPMI-
1640 medium supplemented with 10% fetal bovine
serum (FBS), l mM sodium pyruvate, l penicillin–
streptomycin, 0.l mM non-essential amino acids, 2 mM
L-glutamine, and l vitamin solution (GIBCO, Grand
Island, NY), and incubated in 5% CO2–95% air at 378C.
The cells used in all experiments, with the exception of
PC-3 cells, were between passage 6 and 20. All were free
of Mycoplasma.
Northern BlotAnalysis
mRNA was extracted from subconfluent popula-
tions of cells using the FastTrackTM mRNA isolation kit
(Invitrogen, Inc., San Diego, CA). Poly(Aþ) RNA (5 mg/
well) was fractionated on a 1% formaldehyde/agarose
gel, electrotransferred at 0.8 A to GeneScreen nylon
membranes (DuPont, Boston, MA), and UV cross-
linked with 120,000 mJ/cm2 using a UV Stratalinker
1800 (Stratagene, La Jolla, CA).
Probes forNorthern Blot Analysis
The probes used for Northern hybridization corre-
sponded to full-length human c-Met cDNA (kind gift
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from G. Vande Woude), to full-length EGF-R cDNA
(courtesy of Dr F. Kern and Dr M. Lippman), and to rat
glyceraldehyde-3-phosphate-dehydrogenase (GAPDH).
Each cDNA fragment was radio labeled with the
rediprime random primer labeling kit (Amersham
Corp., Adington Heights, IL) using [a-32P] deoxy-
cytidine 50-triphosphate. All hybridizations were
performed at 658C with 5 106 cpm/blot for 4 hr in
rapid-hyb buffer (Amersham Corp.) following at least a
1 hr pre-hybridization in rapid-hyb buffer (Amersham
Corp.).
Immunoprecipitation andWestern Blotting
Cells were seeded to 6-well plates at a density of
1.5 105 cells per 2.0 ml complete medium and allowed
to attach 24 hr. Following this incubation, the medium
was replaced with 2.0 ml serum-free medium/well and
the cells serum starved for 24 hr. Human recombinant
hepatocyte growth factor (R&D Systems, Minneapolis,
MN) was then added directly to serum-free condi-
tioned medium to a final concentration of 40 ng/ml and
incubated for 15 min in 5% CO2–95% air at 378C. Serum
starved cells were also treated with human epidermal
growth factor (40 ng/ml, GIBCO–BRL) and FBS (5% v/
v) to serve as negative controls for MET activation.
Following growth factor treatment, cells were wash-
ed once on ice with ice-cold PBS containing 5 mM
EDTA and 1 mM sodium orthovanadate and scraped
into 0.25 ml/well ice-cold lysis buffer [1% Triton X-100,
20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol
(v/v), 2 mM EDTA, 1 mM phenylmethylsufonly
fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin,
50 mg/ml trypsin inhibitor, 1 mM sodium orthovana-
date]. Cell lysates were transferred to 1.5 ml tubes and
incubated 20 min on ice to allow complete lysis. Cell
lysates were then clarified by centrifugation (5 min at
16,000g and 48C) and aliquots of each were removed for
protein determination by the DC protein assay (Bio-
Rad, Hercules, CA).
Equal amounts of protein (200 mg/sample) were
diluted in 1.0 ml RIPA buffer [PBS with 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS] and incubated 1 hr at
48C with 0.5 mg/sample anti-human MET mAb UB2
(UBI, Charlottesvile, VA). Following this incubation,
the immune complexes were precipitated overnight at
48C with 20 ml/sample protein A/G sepharose (Onco-
gene, Cambridge, MA). Samples were washed three
times in RIPA buffer, boiled in 5 reducing sam-
ple buffer, and resolved by 7.5% SDS–polyacrylamide
gel electrophoresis (PAGE). Separated proteins were
transferred onto 0.45 mm nitrocellulose membranes
(Amersham Corp.). The filters were blocked with 3%
BSA in Tris-buffered saline (TBS, 20 mM Tris-HCl,
pH 7.5, 150 mM NaCl) and probed with mouse
anti-phospho-tyrosine mAb (1:5,000, UBI) followed
with horseradish-peroxidase conjugated donkey anti-
mouse IgG (IgG–HRP) (1:2,000, Amersham Corp.).
Protein bands were visualized using the ECL detec-
tion system (Amersham Corp.). To demonstrate equal
loading, the blots were stripped and re-probed with
rabbit anti-human MET pAb C-28 (1:1,000, Santa Cruz,
Santa Cruz, CA) followed by donkey anti-rabbit IgG-
HRP (1:2,000, Amersham Corp.).
Cell ProliferationAssay
Cells were seeded to 96-well plates at a density of
1.5 103 cells per 0.2 ml complete medium and allowed
to attach 24 hr. Following this incubation, the cells were
washed once with serum-free RPMI and replaced
with medium containing 0 or 5% FBS (v/v) and 0 or
40 ng/ml of either EGF or HGF in triplicate. Cells were
cultured for 96 hr. The last 2 hr, MTT was added to a
final concentration of 1 mM. The formazan product was
dissolved in DMSO and absorbencies were read on a
Dynatech MR 5000 plate reader at 570 nm.
Analysis of Cell-Free u-PA
The amount of u-PA protein secreted into the culture
medium (cell-free u-PA) was determined by Western
blotting as described previously [22]. Briefly, cells
seeded for Western blotting were washed and treated
with 1% FBS-containing medium supplemented with 0
or 40 ng/ml EGF or HGF for 48 hr in 5% CO2–95% air at
378C. Conditioned medium was prepared for Western
analysis by filtration through 0.2 mm Acrodisc syringe
filters (Gelman Sciences, Ann Arbor, MI). The under-
lying cells were trypsinized and the viable cell number
determined by trypan blue exclusion. To control for
differences in proliferation rates among each treatment
group, aliquots of conditioned media from equal
number of cells (4,000 cells/lane) were diluted with
5 non-reducing sample buffer and resolved by 10%
SDS–PAGE. Filters were probed with polyclonal rabbit
anti-human u-PA #389 (1:1,000, American Diagnostica,
Greenwich, CT) followed with donkey anti-rabbit IgG-
HRP (1:2,000, Amersham Corp.). Cell-free u-PA in 48 hr
conditioned medium was also quantified by Immubind
ELISA kit (American Diagnostica) according to manu-
facture’s protocol using a 1:50 dilution of conditioned
medium.
Cell-free u-PA activity was assessed by Casein/
plasminogen zymography as described with modifica-
tions [30]. Briefly, 48 hr conditioned medium, adjusted
for differences in proliferation rates (2,000 cells/lane),
was separated under non-reducing conditions on a
10% SDS–PAGE containing 0.1% (w/v) casein (Sigma,
St. Louis, MO) and 10 mg/ml human plasminogen
(Calbiochem, La Jolla, CA). Following electrophoresis,
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the gels were incubated at 378C for 2 hr in buffer A
[2.5% (v/v) Triton X-100, 50 mM Tris-HCl (pH 7.5),
0.05% (w/v) sodium azide] followed by 10 hr at 378C in
buffer B [0.15 M NaCl, 100 mM Tris-HCl (pH 7.5)].
Plasminogen-dependent proteolysis was detected as a
clear zone following staining with 0.25% Coomassie
blue in 10% acetic acid/40% methanol.
Densitometry
The u-PA protein levels were quantified in the linear
range of the film on a densitometer (Molecular
Dynamics, Sunnyvale, CA) using the ImageQuant
software program. Sample measurements were calcu-
lated as the ratio of the average volume of the u-PA
specific spot over the cell type untreated control.
InVitro InvasionAssay
In vitro invasion through Matrigel-coated filters was
performed as described with modifications [22].
Briefly, cells were harvested with trypsin, washed once
with serum-free medium, and re-suspended in 5% FBS
medium to a concentration of 5 104 viable cells/ml.
25,000 cells/0.5 ml were added to each well of a 24-
well Matrigel-coated invasion chambers (Becton Dick-
inson, Bedford, MA). The chambers were placed in
wells containing 0.5 ml of RPMI-1640 supplemented
with 5% FBS and 0 or 40 ng/ml of EGF or HGF
and incubated for 48 hr in 5% CO2–95% air at 378C.
At the end of the incubation period, non-invading
cells were removed with a cotton swab from the top
of the filter and the invading cells stained with Hema 31
solution (CMS, Houston, TX). The total number
of invading cells/filter was quantified under 10
magnification.
Where indicated, a final concentration of u-PA
amino-terminal fragment (u-PA-ATF) of 2.5 mM (cor-
responding to amino acids 1–143; kindly provided by
J. Henkin, Abbott Laboratories, Abbott Park, IL) or a
u-PA receptor binding antagonist peptide A˚5 of 50–
500 nM (corresponding to u-PA amino acids 20–30)
was added to the plated cells. A˚5 was synthesized and
cyclized using a covalent linker [31] and inhibits the
binding of 125I-DFP-urokinase to RKO cells with an IC50
of approximately 11 nM [32]. Each compound was
added at the time of cell plating to demonstrate
involvement of the u-PA proteolysis network in the
HGF-stimulated invasion of CaP cells. u-PA-ATF and
A˚5 were non-toxic at the doses utilized and had no
effect on cell viability or proliferation ([32], data not
shown). In separate experiments, a final concentra-
tion of HGF neutralizing antibody (R&D systems) of
10 mg/ml was added to the lower chamber to show
HGF specific effect on invasion.
Statistical Analysis
Cellular proliferation rates, densitometric analyses,
and cell-free u-PA production were compared by the
unpaired Student’s t-test.
RESULTS
mRNAand ProteinAnalysis ofMETExpression in
HighVersus LowMetastaticHumanCaPCells
Given that MET expression directly correlates with
high-grade prostatic adenocarcinomas and metastases
in humans, we examined whether the PC-3 isogenic cell
lines express the MET molecule. Northern blot analyses
of steady-state transcripts demonstrated that each of
the cell lines tested express high and equivalent
amounts of the 7.0 kb Met message (Fig. 1, lanes A–
D). Western blot analysis with anti-sera to MET also
demonstrated that the MET protein was equally
expressed among each cell line (Fig. 2). Biological
activity was demonstrated following HGF treatment as
shown by the specific phosphorylation of the 145 kDa b
chain of MET (Fig. 2, lanes D,H,L,P). Only 5% serum
and hEGF were included as negative controls for MET
phosphorylation. These data demonstrate that the PC-3
isogenic cell lines express high levels of the functional
HGF receptor, MET.
Fig. 1. Steady-statemRNAanalysisofPC-3isogenicprostatecar-
cinoma cell lines.Poly(Aþ)mRNAwas isolated fromPC-3, parental
PC-3M, low-metastatic PC-3M-Pro4, andhigh-metastatic PC-3M-
LN4 CaP cells by oligo (dT)-cellulose chromatography. A 5 mg/lane
was fractionated on a 1% formaldehyde agarose gel, electrotrans-
ferred to nylon membrane, and hybridized with cDNA probes to
MET, EGF-R, and as a loading control, glyceraldehyde 3-phosphate
dehydrogenase(GAPDH).
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Effect ofHGFonthe Proliferation ofMetastatic
HumanCaPCells
Despite the presence of functional MET protein,
treatment with recombinant human HGF resulted in
only weak proliferative capacity in each of the cell lines
tested. Figure 3 shows the mean percent increase over
untreated controls standard deviation of triplicate
wells from a representative MTT proliferation assay.
The data indicate that each of the CaP cell types was
similarly stimulated to a maximum of 30% above
untreated controls following treatment with 40 ng/ml
HGF in 5% serum containing medium. These data
demonstrate that HGF weakly stimulates the ancho-
rage-dependent growth of the PC-3 isogenic cell lines
in vitro.
Induction of u-PAinMetastatic CaPCells
Following LigandActivation ofMET
As HGF treatment stimulated anchorage-dependent
growth similarly in PC-3 CaP cells of different meta-
static potentials, we analyzed the relationship between
HGF/MET signaling and u-PA protein production.
Analyses of u-PA protein secreted into the culture
medium (cell-free u-PA) in both the low metastatic PC-
3M-Pro4 cells and the high metastatic PC-3M-LN4 cells
is shown in Figure 4. Cell-free u-PA could be detected
in untreated control cells after 48 hr. Consistent with
similar levels of functional MET protein in both cell
lines, exposure to HGF (40 ng/ml) resulted in a 2–3-
fold elevation over untreated controls in both low
metastatic PC-3M-Pro4 and highly metastatic PC-3M-
LN4 cells, respectively (Fig. 4a, lanes D,G). EGF did not
stimulate cell-free u-PA protein production. Enzyme-
linked immunosorbant assay (ELISA) for cell-free u-PA
protein confirmed the HGF-stimulated increase ob-
served by Western blotting (Table I). Casein/plasmi-
nogen zymography for u-PA activity following HGF
treatment showed enhanced protein activity similar
to that observed in the Western blot and ELISA
analyses. These data indicate that HGF increases cell-
free u-PA protein levels directly correlating with
enhanced activity of u-PA (Fig. 4b, lanes D,G). These
results indicate that ligand activation of MET results in
the up-regulation of functional, cell-free u-PA protein
in metastatic variants of human PC-3 CaP cells.
Induction of InVitro Invasion inMetastatic
CaPCells Following LigandActivation ofMET
To determine if a >3-fold increase in cell-free u-PA
protein is physiologically relevant, in vitro invasion
assays were performed. Figure 5a shows the fold in-
crease over untreated controls, mean the standard
error, of three separate experiments comparing the
high-metastatic PC-3M-LN4 cells. These data indicate
that HGF, but not EGF or 5% serum, increased the in-
vasion of highly metastatic PC-3M-LN4 cells greater
than 59-fold over untreated control cells (P< 0.002).
HGF similarly stimulated the invasion of low meta-
static PC-3M-Pro4 cells 5-fold consistent with the
observed increase in cell-free u-PA in these cells (data
not shown). These results support a role for HGF in the
invasion of metastatic CaP cells in vitro.
To test the direct involvement of u-PA in HGF-
stimulated in vitro invasion, the assays were repeated
in the presence of the specific u-PA receptor inhibitors
u-PA-amino terminal fragment (u-PA-ATF) or the
u-PA receptor binding antagonist peptide, A˚5. The
addition of u-PA-ATF at 2.5 mM resulted in greater than
50% inhibition of HGF-stimulated invasion (P< 0.02;
Fig. 5B). The addition of A˚5 at 50–500 nM resulted in a
dose-dependent inhibition to baseline of PC-3M-LN4
HGF-stimulated invasion (Fig. 5C). Further, the addi-
tion of HGF neutralizing antibody eliminated the HGF-
stimulated invasion showing that HGF is responsible
Fig. 2. Western blot analysis for functional MET protein. PC-3,
parental PC-3M, low-metastatic PC-3M-Pro4, andhigh-metastatic
PC-3M-LN4 CaP cells were plated in complete medium, serum-
starved18 hr, and treated with HGF or EGF at 40 ng/ml or serum
(5% v/v) for15 min prior to lysis.Two hundredmicrograms of total
proteinwasimmunoprecipitatedwithanti-METUB2mAbandsepa-
ratedby 7.5% SDS^PAGE.Nitrocellulose filterswere probed sepa-
rately with anti-sera specific to phosphotyrosine for activity and
MET C-28 pAb for loading. The immunoreactive bands were
detected by incubation with peroxidase-conjugated secondary
anti-sera and visualizedusing the ECL system. 5% serum andhEGF
wereincludedasnegativecontrols forMETphosphorylation.
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Fig. 3. EffectofHGFonproliferationinvitro.PC-3,parentalPC-3M,low-metastaticPC-3M-Pro4,andhigh-metastaticPC-3M-LN4CaPcells
(1,500/well)weretreatedwith0or40ng/mlHGForEGFin0or5%serum-containingmediumfor96hr.MTT(1mM)wasaddedfor thelast2hrof
the incubation.Formazanproductwas solubilized inDMSOandmeasuredatOD570 nm.The data is presented as themeanpercent increase
overuntreatedcontrols standarddeviationof triplicatewells fromarepresentativeMTTproliferationassay.
Fig. 4. HGFtreatmentincreasescell-freeurokinase-typeplasminogenactivator(u-PA)proteinproduction.A:Low-metastaticPC-3M-Pro4
andhigh-metastatic PC-3M-LN4CaPcells (1.5105/well) were treatedwith or 0 or 40 ng/mlHGF or EGF in1% serumcontainingmedium for
48 hr. Conditioned medium from equal numbers of cells (4,000/lane) was resolved under non-reducing conditions by 10% SDS^PAGE
and transferred to nitrocellulose. Filters were probed with anti-serum specific to human u-PA, detected by incubation with peroxidase-
conjugated secondary anti-serum, and visualized using the ECL system. B: Effect of HGF on u-PA activity. Forty-eight hours serum-free
conditionedmedium from equal numbers of cells (2,000/lane) was resolved under non-reducing conditions by10% SDS^PAGE impregnated
with casein andplasminogen.Following abriefrenaturationperiod, gelswere stainedwith coomassieblue.Zones of clearing visible after light
destainingindicateactiveprotease.
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TABLE I. Effects ofHGFonCell-Free u-PAProductionbyHumanCaPCellsa
PC-3 PC-3M PC-3M-Pro4 PC-3M-LN4
w/o Growth Factor 1.0 0.1 (576.2) 1.0 0.1 (132.6) 1.0 0.1 (948.8) 1.0 0.2 (174.4)
EGF, 40 ng/ml 1.2 0.2 (692.5) 0.7 0.0 (98.6) 1.3 0.1 (1213.9) 1.5 0.1 (264.5)
HGF, 40 ng/ml 1.1 0.0 (631.3) 1.6 0.2 (215.1) 1.1 0.2 (1006.9) 3.9 0.0* (685.8)
aThe data is presented as the fold increase over untreated control standard deviation of duplicate wells. The mean protein concentration
of cell-free u-PA (ng/ml/106 cells) appears in parentheses. One representative experiment of four.
*P< 0.002, PC-3M-LN4 compared to PC-3, PC-3M, or PC-3M-Pro4.
Fig. 5. HGFinducesinvitroinvasionviaau-PAdependentmechanism.A:High-metastaticPC-3M-LN4CaPcells(25,000/0.5ml)wereseeded
inserum-containingmediumtotheupperchamberofaMatrigelinvasionchamber.Fivepercentserum-containingmediumsupplementedwith0
or40ng/mlHGForEGFwasplacedinthelowerchamber.After48hr,invadingcellswerestainedandquantified.Thedataispresentedas thefold
increase over untreatedcontrols,mean standarderror, of three separate experiments.B: In a separate experiment, 2.5mMu-PAreceptor
antagonistu-PA-amino terminal fragment (u-PA-ATF)was added to theupper chamber and the effecton invasionquantified.The data is pre-
sentedas the foldincreaseoveruntreatedcontrol,mean standarddeviation,ofduplicatewells.C: Ina separateexperiment,0 ^500nMu-PA
receptor antagonistpeptide,—5,wasaddedandtheeffectoninvasionquantified,mean standarddeviation,ofduplicatewells.D: A finalcon-
centration ofHGF neutralizing antibodyof10mg/mlwas added to the lower chamber to showHGF specific effecton invasion.The data is pre-
sentedas the foldincreaseoveruntreatedcontrols,mean standarderror,of three separateexperiments.
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for the u-PA dependent invasion (Fig. 5D). Taken
together, these data demonstrate that HGF specifically
increases the in vitro invasion of metastatic human CaP
cells through the up-regulation of the u-PA proteolysis
network.
DISCUSSION
In order for a tumor cell to colonize a distant site, it
must successfully interact with the organ microenvir-
onment. Chung et al. [4] hypothesized that the
predilection of CaP cells to metastasize to the bone is
a result of reciprocal interactions between tumor and
stromal-derived growth factors [33]. The strong asso-
ciation of MET expression in bone lesions of CaP and
the high expression of HGF in the bone stroma led us to
examine the role of HGF/MET signaling in CaP
invasion and metastasis.
In this study, human, isogenic CaP cells with dif-
ferent metastatic propensities were shown to express
high and equal amounts of a functional MET protein.
However, despite this functional receptor, treatment of
these cells with HGF proved to be weakly mitogenic,
stimulating each cell type approximately 30% above
untreated controls. Analysis of protease production in
response to HGF revealed that HGF increased the
levels of cell-free u-PA, approximately 2–3-fold in both
low metastatic PC-3M-Pro4 cells and highly metastatic
PC-3M-LN4 cells. The modest increase in cell-free u-PA
protein following HGF treatment, however resulted in
a significant increase in in vitro invasion. In Matrigel-
coated invasion chamber assays, chemo-attractant
HGF, but not 5% serum or EGF, stimulated the invasion
of the high metastatic PC-3M-LN4 cells 59-fold above
untreated controls. Furthermore, treatment with non-
toxic doses of the specific urokinase receptor inhibitors
u-PA-ATF or A˚5 resulted in a dose-dependent reduc-
tion of the HGF-stimulated invasion. Taken together,
these results support the biological significance of u-PA
up-regulation in response to HGF in metastatic CaP
cells.
Recently, others have reported that HGF enhances
the in vitro attachment to and subsequent invasion
through Matrigel of DU145 and PC-3 human CaP cells
[34–36]. It has also been shown that the serum level
of HGF in men with metastatic CaP is significantly
elevated compared to men with localized disease [37].
These data are in agreement with our own and further
support a role for HGF in CaP invasion and metastasis.
The analyses presented herein support a mechanism
where MET positive CaP cells utilize bone stromal-
derived HGF to up-regulate u-PA and promote inva-
sion of the skeleton.
In addition to mediating bone-specific metastasis in
CaP, HGF/MET may also participate in the formation
of an osteoblastic lesion. This is a unique feature of CaP
metastases and represents 95% of all bone metastases
formed by CaP [38]. Recently, HGF was described as a
factor coupling osteoblast/osteoclast functions to the
re-organization of normal bone structure [39,40]. Both
osteoblasts and osteoclasts were shown to express a
functional MET. HGF is a strong osteoblast mitogen
and it stimulates chemotactic migration and bone re-
sorption by osteoclasts in the presence of osteoblasts. It
is in this fashion that HGF may participate in the
clinical manifestations of CaP, the formation of an
osteoblastic metastasis.
Based on our in vitro findings, interfering with CaP
metastasis by abrogating either the u-PA proteolysis
network or HGF/MET signaling may be feasible.
Indeed, the direct inhibition of u-PA by the enforced
expression of the plasminogen activator inhibitor type
1 (PAI-1) or a u-PA dominant negative protein have
both been shown to reduce or block primary tumor
growth, tumor-associated angiogenesis, and experi-
mental metastasis of transfected CaP cells versus con-
trols [41–43]. The same has been described for small
molecule u-PA inhibitors such as Amiloride, p-amino-
benzamidine, and B-428 in various animal models [44–
46]. Currently, experiments are underway to directly
test the role of u-PA and MET in CaP metastasis in vivo
through the use of u-PA specific inhibitors or MET
specific ribozymes, respectively.
In conclusion, we provide evidence that HGF stimu-
lates the secretion of biologically active u-PA and
enhances in vitro invasion through Matrigel of human
CaP cells with differing metastatic potential. These data
support a role for u-PA in CaP cell invasion as specific
inhibitors to the urokinase receptor inhibited the HGF-
stimulated invasion. Collectively, these data support a
model that HGF/MET participate in CaP invasion and
metastasis.
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